Pomalyst

(Pomalidomide)

ApprovedSmall molecule

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Pomalidomide is used to treat multiple myeloma, a type of blood cancer affecting bone marrow cells. It works by helping the immune system fight cancer cells and by directly slowing cancer cell growth.[2] Pomalyst is currently approved and in use across 40 indications[4].[1]

Pomalyst is one of 777 small molecule programs targeting Macroglobulinemia. It is currently in Approved.

Indications

242

Total Trials

Active Trials

776

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

MacroglobulinemiaActive, not recruiting

ToxicityActive, not recruiting

Primary MyelofibrosisApproved

Central Nervous System LymphomaActive, not recruiting

AL AmyloidosisActive, not recruiting

Central Nervous System NeoplasmApproved

LymphomaActive, not recruiting

Immune System DiseaseActive, not recruiting

Pulmonary FibrosisApproved

Kaposi's SarcomaApproved

MacroglobulinemiaPhase 1

Active, not recruiting

ToxicityPhase 2

Active, not recruiting

Primary MyelofibrosisApproved

Approved

Central Nervous System LymphomaPhase 1

Active, not recruiting

AL AmyloidosisPhase 2

Active, not recruiting

Central Nervous System NeoplasmApproved

Approved

LymphomaPhase 1

Active, not recruiting

Immune System DiseaseApproved

Active, not recruiting

Pulmonary FibrosisApproved

Approved

Kaposi's SarcomaApproved

Approved

Showing 10 of 40 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

2 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

PEG-Intron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ARecruiting

Anti-PD-1 Antibody

NCT06832228

N/ANot yet recruiting

Combination Therapy

NCT07015021

Q4 2026

Phase 1Active, not recruiting

Multiple Myeloma

NCT05556798

Phase 2Active, not recruiting

Kaposi Sarcoma

NCT04577755

Phase 1/2Not yet recruiting

Multiple Myeloma

NCT05581875

Phase 2Active, not recruiting

Multiple Myeloma

NCT04925193

Clinical

Trials by Indication[1]

Multiple Myeloma119 trials

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Completed·GGWT-TUD GmbH·Phase 2·NCT03731832·66 enrolled

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Unknown status·CCristina Gasparetto·Phase 1/2·NCT01754402·56 enrolled

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 1·NCT02939183·61 enrolled

Show 116 more trials

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02612779·74 enrolled

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Terminated· AbbVie logo

AbbVie·Phase 1·NCT04895410·8 enrolled

The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)

Completed·KKosin University Gospel Hospital·Phase 2·NCT03242460·55 enrolled

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06948084·80 enrolled

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

Completed·MMayo Clinic·Phase 2·NCT00558896·378 enrolled

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05556798·9 enrolled

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Completed· Roche logo

Roche·Phase 1·NCT02431208·85 enrolled

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

Recruiting·TThe Royal Wolverhampton Hospitals NHS Trust··NCT04234022·70 enrolled

Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

Terminated·MMaimónides Biomedical Research Institute of Córdoba·Phase 2·NCT04243109·6 enrolled

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Terminated·UUniversitätsklinikum Hamburg-Eppendorf·Phase 3·NCT05675319·28 enrolled

Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide

Completed·FFondazione EMN Italy Onlus·Phase 1/2·NCT01166113·67 enrolled

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

Completed·UUniversity of Arkansas·Phase 2·NCT01177735·71 enrolled

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00833833·259 enrolled

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Active, not recruiting·MMayo Clinic·Phase 1/2·NCT04764942·39 enrolled

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Completed·UUniversity Hospital, Lille·Phase 2·NCT01745640·63 enrolled

Combination Study for High Risk Multiple Myeloma Patients

Terminated·OOncotherapeutics·Phase 2·NCT03104270·13 enrolled

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01568294·12 enrolled

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05236621·85 enrolled

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT04925193·18 enrolled

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT05020236·944 enrolled

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·MMayo Clinic·Phase 1/2·NCT01212952·50 enrolled

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01311687·455 enrolled

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01592370·320 enrolled

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05455320·864 enrolled

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02807454·37 enrolled

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02103335·38 enrolled

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01998971·240 enrolled

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Terminated· Pfizer logo

Pfizer·Phase 1·NCT03582033·83 enrolled

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01734928·559 enrolled

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01712789·682 enrolled

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Withdrawn·—·Phase 2·NCT03841565

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Active, not recruiting·EEuropean Myeloma Network B.V.·Phase 3·NCT05028348·117 enrolled

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT04302324·9 enrolled

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01745588·23 enrolled

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT03713294·37 enrolled

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

Active, not recruiting·FFondazione EMN Italy Onlus·Phase 2·NCT04124497·45 enrolled

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Terminated· Amgen logo

Amgen·Phase 1·NCT03287908·174 enrolled

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT03202628·8 enrolled

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT02569320·9 enrolled

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Completed·OOncotherapeutics·Phase 1/2·NCT02206425·45 enrolled

A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

Withdrawn· Takeda logo

Takeda·Phase 4·NCT05183139

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Active, not recruiting· Sanofi logo

Sanofi··NCT04458831·583 enrolled

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01946152·21 enrolled

Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Terminated· AbbVie logo

AbbVie·Phase 1·NCT02462525·74 enrolled

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05572515·614 enrolled

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

Completed·EEuropean Myeloma Network B.V.·Phase 1/2·NCT02185820·57 enrolled

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

Unknown status·OOncotherapeutics·Phase 1/2·NCT01541332·70 enrolled

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01946477·186 enrolled

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Active, not recruiting· GSK logo

GSK·Phase 2·NCT04126200·208 enrolled

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT04843579·4 enrolled

Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

Completed·AAjai Chari·Phase 2·NCT02176213·35 enrolled

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT05730036·410 enrolled

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Terminated· AbbVie logo

AbbVie·Phase 2·NCT03567616·8 enrolled

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Active, not recruiting· AbbVie logo

AbbVie·Phase 3·NCT03539744·265 enrolled

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02616640·114 enrolled

Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma

Unknown status·LLanZhou University·N/A·NCT05378971·15 enrolled

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Completed·—·Phase 1/2·NCT02119468·32 enrolled

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT02718833·52 enrolled

Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

Unknown status·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT02004275·118 enrolled

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02654132·117 enrolled

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Terminated·OOncotherapeutics·Phase 2·NCT02294357·45 enrolled

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Recruiting·UUniversity of Chicago·Phase 2·NCT05789303·83 enrolled

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

Approved for marketing· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT01632826

A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Withdrawn· Teva logo

Teva·Phase 1·NCT04392648

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Recruiting·CCellCentric Ltd.·Phase 2·NCT07096778·100 enrolled

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Active, not recruiting· GSK logo

GSK·Phase 3·NCT06956170·21 enrolled

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 3·NCT07452198·358 enrolled

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Completed· GSK logo

GSK·Phase 1·NCT03828292·15 enrolled

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Recruiting·MMedical College of Wisconsin·Phase 2·NCT04835129·53 enrolled

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Active, not recruiting· Takeda logo

Takeda·Phase 1·NCT03984097·50 enrolled

Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT02576977·251 enrolled

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Terminated·MMayo Clinic·Phase 2·NCT05288062·17 enrolled

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Withdrawn·—·Phase 2·NCT03227432

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Suspended·HHackensack Meridian Health·Phase 2·NCT04661137·96 enrolled

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Terminated·WWashington University School of Medicine·Phase 1·NCT01537861·7 enrolled

Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma

Unknown status· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 3·NCT02916420·73 enrolled

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02011113·36 enrolled

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02726581·170 enrolled

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT05259839·283 enrolled

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

Completed·MMayo Clinic·Phase 2·NCT01794039·9 enrolled

A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 2·NCT03170882·122 enrolled

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Terminated·PPharmacyclics LLC.·Phase 1/2·NCT02548962·11 enrolled

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02400242·85 enrolled

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT05669989·70 enrolled

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01324947·74 enrolled

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Active, not recruiting·PPoitiers University Hospital·Phase 2·NCT04287855·82 enrolled

A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma

Terminated· Amgen logo

Amgen·Phase 1·NCT01999335·33 enrolled

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Recruiting·KKaryopharm Therapeutics Inc·Phase 1/2·NCT02343042·300 enrolled

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Not yet recruiting· GSK logo

GSK·Phase 2·NCT07227311·200 enrolled

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

Completed·YYale University·Phase 2·NCT01319422·40 enrolled

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT07018050·160 enrolled

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Completed·KKoen van Besien·Phase 1·NCT03143985·18 enrolled

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Withdrawn·MMedical College of Wisconsin·Phase 1·NCT04355039

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Terminated·UUniversity of California, San Diego·Phase 2·NCT03590652·23 enrolled

Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma

Terminated·SSwiss Cancer Institute·Phase 2·NCT03520985·34 enrolled

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT03030261·25 enrolled

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Completed·MMorphoSys AG·Phase 1/2·NCT01421186·91 enrolled

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Terminated·CCriterium, Inc.·Phase 1/2·NCT01464034·136 enrolled

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

Active, not recruiting·UUniversity of Leeds·Phase 2·NCT02406222·124 enrolled

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07138209·228 enrolled

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

Completed· Sanofi logo

Sanofi·Phase 3·NCT02990338·307 enrolled

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Terminated· Teva logo

Teva·Phase 1·NCT05556616·15 enrolled

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Recruiting·—·Phase 2·NCT04508790·29 enrolled

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01497093·34 enrolled

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

Terminated·HHackensack Meridian Health·Phase 2·NCT04700176·1 enrolled

Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Withdrawn·MMassachusetts General Hospital·Phase 1·NCT03657420

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05083169·587 enrolled

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·UUniversity of Chicago·Phase 1/2·NCT01665794·25 enrolled

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Not yet recruiting·HHellenic Society of Hematology·Phase 1/2·NCT05581875·48 enrolled

CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.

Active, not recruiting·CCancer Trials Ireland·Phase 1·NCT04667663·16 enrolled

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

Active, not recruiting·JJoseph Tuscano·Phase 1/2·NCT02542657·30 enrolled

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06232707

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Terminated·PPETHEMA Foundation·Phase 1·NCT03023527·6 enrolled

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Unknown status·SSun Yat-sen University·Phase 1/2·NCT04762745·56 enrolled

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

Recruiting·MMassachusetts General Hospital·Phase 2·NCT05922501·50 enrolled

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Terminated·AAshraf Badros·Phase 1/2·NCT02289222·48 enrolled

Dexamethasone11 trials

Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM

Unknown status·SShanxi Bethune Hospital·Phase 2·NCT06255847·43 enrolled

Ixazomib + Pomalidomide + Dexamethasone In MM

Active, not recruiting·—·Phase 1/2·NCT04094961·52 enrolled

IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma

Completed·UUniversity Hospital, Lille·Phase 2·NCT01053949·84 enrolled

Show 8 more trials

SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients

Completed· Sanofi logo

Sanofi·Phase 1·NCT02283775·54 enrolled

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Recruiting·—·Phase 2·NCT04176718·43 enrolled

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT05405166·531 enrolled

Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone

Unknown status·SSamsung Medical Center·Phase 2·NCT05509374·33 enrolled

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Unknown status·HHellenic Society of Hematology·Phase 2·NCT05298683·108 enrolled

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT01432600·80 enrolled

Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans

Unknown status·IInstituto de Seguridad y Servicios Sociales de los Trabajadores del Estado·Phase 2·NCT03601624·18 enrolled

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Recruiting·EEmory University·Phase 2·NCT05208307·34 enrolled

Pomalidomide10 trials

Study of Pomalidomide in Anal Cancer Precursors

Unknown status·KKirby Institute·Phase 2·NCT03113942·26 enrolled

A Pilot Bioequivalence Study of Pomalidomide

Completed· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT03424928·12 enrolled

A Pilot Bioequivalence Study of Pomalidomide

Unknown status·MMegalabs·Phase 1·NCT06058689·10 enrolled

Show 7 more trials

Pomalidomide as an Immune-enhancing Agent for the Control of HIV

Recruiting·UUniversity of Aarhus·Phase 1/2·NCT06660498·32 enrolled

Pomalidomide for the Treatment of Bleeding in HHT

Completed·TThe Cleveland Clinic·Phase 2·NCT03910244·145 enrolled

Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study

Completed·AAmsterdam UMC, location VUmc·Phase 4·NCT05555329·12 enrolled

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01474330·33 enrolled

Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant

Withdrawn·NNatalie Callendar·Phase 2·NCT04584307

Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05390749·50 enrolled

A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01707407·32 enrolled

AL amyloidosis6 trials

Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2·NCT01510613·28 enrolled

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

Recruiting·YYongyong MA·N/A·NCT06455748·20 enrolled

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01807286·3 enrolled

Show 3 more trials

A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis

Completed·—·Phase 1/2·NCT01570387·27 enrolled

Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

Recruiting·—·Phase 2·NCT06342466·40 enrolled

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Terminated·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT01728259·18 enrolled

Lenalidomide3 trials

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Completed· Amgen logo

Amgen·Phase 2·NCT04191616·54 enrolled

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

Terminated·OOncopeptides AB·Phase 3·NCT03151811·495 enrolled

Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

Unknown status·JJuan Du·Phase 2·NCT04941937·90 enrolled

43 more indications

Amyloidosis2 trials

Daratumumab for Patients With Light Chain Amyloidosis

Recruiting·NNanjing University School of Medicine·N/A·NCT06376214·100 enrolled

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT04270175·15 enrolled

Central Nervous System Lymphoma2 trials

Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma

Completed·MMayo Clinic·Phase 1·NCT01722305·29 enrolled

A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1/2·NCT06554561·43 enrolled

Myelofibrosis2 trials

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01178281·267 enrolled

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00463385·88 enrolled

Kaposi Sarcoma2 trials

Pomalidomide for Kaposi Sarcoma in People With or Without HIV

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01495598·28 enrolled

Pomalidomide Treatment in Patients With Kaposi Sarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04577755·45 enrolled

Lymphoma2 trials

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT02228512

Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

Completed·MMayo Clinic·Phase 1·NCT03798314·3 enrolled

Treatment2 trials

A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders

Completed·UUniversity Health Network, Toronto·Phase 2·NCT03959358·10 enrolled

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02719613·67 enrolled

Macroglobulinemia1 trial

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Terminated·—·Phase 1·NCT01078974·7 enrolled

Soft Tissue Sarcoma1 trial

Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00717522·7 enrolled

Gemcitabine1 trial

CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas

Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT00540579·23 enrolled

Blood Cancer1 trial

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Withdrawn·EEpizyme, Inc.·Phase 1/2·NCT05205252

Refractory1 trial

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

Recruiting·NNanjing IASO Biotechnology Co., Ltd.·Phase 3·NCT06464991·240 enrolled

Toxicity1 trial

Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT02158702·100 enrolled

Renal insufficiency1 trial

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02045017·81 enrolled

Anti-PD-1 Antibody1 trial

Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL

Recruiting·ZZhejiang Cancer Hospital·N/A·NCT06832228·30 enrolled

Idiopathic Pulmonary Fibrosis1 trial

Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis

Withdrawn·SStanford University·Phase 2·NCT01135199

Diffuse Large B-Cell Lymphoma1 trial

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

Recruiting·RRuijin Hospital·Phase 2·NCT05348213·76 enrolled

Interstitial Lung Disease1 trial

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01559129·23 enrolled

Age1 trial

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Recruiting· Sanofi logo

Sanofi·Phase 1/2·NCT04643002·258 enrolled

Chronic Graft Versus Host Disease1 trial

Pomalidomide for Chronic Graft-versus-Host Disease

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01688466·34 enrolled

Primary Brain Tumor1 trial

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03257631·53 enrolled

Relapsed/Refractory1 trial

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

Completed·WWeill Medical College of Cornell University·Phase 2·NCT01159574·121 enrolled

Central Nervous System Tumor1 trial

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02415153·29 enrolled

Elderly Patients1 trial

Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients

Recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT05809180·35 enrolled

Phase II1 trial

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

Withdrawn·UUniversity of Arkansas·Phase 2·NCT02578121

Advanced Malignancies1 trial

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Terminated· Incyte logo

Incyte·Phase 1/2·NCT02265510·83 enrolled

Hereditary Hemorrhagic Telangiectasia1 trial

Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study

Completed·TThe Cleveland Clinic·Phase 1·NCT02287558·9 enrolled

Phase 11 trial

A Phase 1 QT Study in Healthy Male Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01986894·72 enrolled

Myelodysplastic Syndrome1 trial

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02029950·50 enrolled

Maintenance Treatment1 trial

Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment

Terminated·FFondazione EMN Italy Onlus·Phase 3·NCT03440411·9 enrolled

Central Nervous System1 trial

Marizomib Central Nervous System (CNS)

Withdrawn·—·Phase 2·NCT05050305

Mantle Cell Lymphoma1 trial

Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

Recruiting·PPeking University Third Hospital·N/A·NCT07257510·34 enrolled

Elderly1 trial

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT05911321·6 enrolled

Relapsed or Refractory1 trial

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06208150·795 enrolled

Combination Therapy1 trial

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT07015021·72 enrolled

Maximum Tolerated Dose1 trial

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00537511·22 enrolled

Waldenstrom macroglobulinemia1 trial

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01198067·15 enrolled

Myeloproliferative Neoplasms1 trial

Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage

Completed·UUniversity of Ulm·Phase 2·NCT00949364·103 enrolled

Daratumumab1 trial

A Study of Daratumumab

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05438043·500 enrolled

TED1 trial

Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex

Completed·SStichting European Myeloma Network·Phase 3·NCT03180736·304 enrolled

Sickle Cell Disease1 trial

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01522547·12 enrolled

Liposomal Doxorubicin1 trial

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02659930·62 enrolled

Plasma Cell Leukemia1 trial

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Completed·MMayo Clinic·Phase 2·NCT02547662·17 enrolled

Unspecified3 trials

Food Effect and CYP1A2 Induction Study in Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02168205·55 enrolled

PVd Versus Vd in NDMM Patients With RI

Unknown status·RRenJi Hospital·Phase 2·NCT05432414·79 enrolled

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Withdrawn·AAlliance Foundation Trials, LLC.·Phase 1/2·NCT05408026

Regulatory

FDA Approval Timeline[5]

Feb 8, 2013

POMALYST

NDA NDA204026

Sources

References

[1]
ClinicalTrials.gov — 242 trial records for Pomalidomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Pomalyst drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Pomalidomide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Pomalidomide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA204026). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Pomalyst. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Karuna Therapeutics, Inc., a Bristol Myers Squibb company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: CRL4(CRBN) E3 Ubiquitin Ligase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Patent Landscape[6]

Patent Cliff

May 19, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10555939May 19, 2030

9993467May 19, 2030

9993467*PEDNov 19, 2030

10555939*PEDNov 19, 2030

8828427Jun 21, 2031

1 more patents

8828427*PEDDec 21, 2031

Pomalyst

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Multiple Myeloma119 trials

Dexamethasone11 trials

Pomalidomide10 trials

AL amyloidosis6 trials

Lenalidomide3 trials

Amyloidosis2 trials

Central Nervous System Lymphoma2 trials

Myelofibrosis2 trials

Kaposi Sarcoma2 trials

Lymphoma2 trials

Treatment2 trials

Macroglobulinemia1 trial

Soft Tissue Sarcoma1 trial

Gemcitabine1 trial

Blood Cancer1 trial

Refractory1 trial

Toxicity1 trial

Renal insufficiency1 trial

Anti-PD-1 Antibody1 trial

Idiopathic Pulmonary Fibrosis1 trial

Diffuse Large B-Cell Lymphoma1 trial

Interstitial Lung Disease1 trial

Age1 trial

Chronic Graft Versus Host Disease1 trial

Primary Brain Tumor1 trial

Relapsed/Refractory1 trial

Central Nervous System Tumor1 trial

Elderly Patients1 trial

Phase II1 trial

Advanced Malignancies1 trial

Hereditary Hemorrhagic Telangiectasia1 trial

Phase 11 trial

Myelodysplastic Syndrome1 trial

Maintenance Treatment1 trial

Central Nervous System1 trial

Mantle Cell Lymphoma1 trial

Elderly1 trial

Relapsed or Refractory1 trial

Combination Therapy1 trial

Maximum Tolerated Dose1 trial

Waldenstrom macroglobulinemia1 trial

Myeloproliferative Neoplasms1 trial

Daratumumab1 trial

TED1 trial

Sickle Cell Disease1 trial

Liposomal Doxorubicin1 trial

Plasma Cell Leukemia1 trial

Unspecified3 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News